Enhancement of the Antiviral Activity of Poly (A-U) by Adriamycin and Daunomycin

Abstract

The role of adriamycin (ADR) and daunomycin (DMN) in modulating the antiviral activity of poly (adeylate-uridylate) (poly (A-U)) was examined using a human foreskin fibroblast – vesicular stomatitis virus (HSF-VSV) bioassay in which the concentration of poly (A-U) was fixed at 0.05 mm or 0.2 mm while the ADR or DMN concentration was varied to produce ADR (or DMN)/ribonucleotide ratios ranging from 1:16 to 2:1. Poly (A-U), ADR and DMN were not efficacious antiviral agents when tested individually at the concentrations employed in the ADR (or DMN)/poly (A-U) combinations. When the ADR or DMN was combined with the poly (A-U) to produce ADR (or DMN)/poly (A-U) ratios of 1/6, the 50% effective doses (ED₅₀) of the poly (A-U), ADR and DMN decreased 18, 104, and 185-fold, respectively. However, when ADR or DMN was combined with polyriboinosinic-polyribocytidylic acid [poly (I) · poly (C)], the ED₅₀ of the ADR, DMN and the poly (I) · poly (C) were not affected. Interferon neutralization studies indicated that ADR, DMN, poly (A-U) and the ADR (or DMN)/poly (A-U) combination induced the production of interferon-beta (IFN-β). The amount of IFN produced by the ADR (or DMN)/poly (A-U) combinations was equal to the sum of the IFN prduced by their constituents. These results indicate that the ADR and DMN potentiate the antiviral activity of the poly (A-U) without affecting the amount of IFN induced. The direct viral inactivation study demonstrated that ADR, DMN, poly (A-U) and the ADR (or DMN)/poly (A-U) combinations do not inactivate the VSV at concentrations near the ED₅₀.

References

Ash

R.J.

, and Diekma

K.A.

(1987) Inhibition of herpes simplex virus replication by anthracycline compounds. Antiviral Res 8: 71–83.

Bauer

D.J.

Selway

J.W.T.

Batchelor

J.F.

Tisdale

Caldwell

I.C.

, and Young

D.A.B.

(1981) 4′, 6-dichloroflavin (BW683C), a new anti-rhinovirus compound. Nature 292: 369–370.

Bernard

Paul

Boiron

Jacquillat

C.I.

, and Maral

(1969) Rubidomycin, In: Rubidomycin (eds Bernard

Paul

Boiron

Jacquillat

C.I.

, and Maral

. Springer-Verlag, New York, pp. 24–61.

Biogenics Research Corporation (1979) Technical data sheet. Chardon, OH.

Blanchard

J.C.

Schneider

Y.J.

Baurain

, and Trouet

(1981) Accumulation, metabolism and subcellular localization of daunorubicin, doxorubicin and their DNA-complexes in rat heart ventricle. Eur J Cancer 17: 297–305.

Bossa

Botturi

Dubini

, and Galatulas

(1975) Potentiation of the antiviral activity of daunomycin by desipramine. Minerva Med 66: 2318–2321.

Cheng

C.C.

Zbinden

, and Zee-Cheng

R.K.Y.

(1979) Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. J Pharm Sci 68: 393–396.

Chuang

L.F.

Chuang

R.Y.

Acton

E.M.

Israel

, and Yu

(1987) Effect of morpholinyldraiamycin analogs and adriamycin on the activities of DNA polymerase α and RNA polymerase II of chicken leukemia cells. J Pharm Exp Ther 242: 372–377.

Cohen

Harley

E.H.

, and Rees

K.R.

(1969) Antiviral effect of daunomycin. Nature 222: 36–38.

10.

De Clercq

, and Torrence

P.F.

(1977) Comparative study of various double-stranded RNAs as inducers of human interferon. J Gen Virol 37: 619–623.

11.

Diederich

Lodemann

, and Wacker

(1972) New type of interferon inducer. Naturwissenschaften 59: 172–173.

12.

Diederich

Lodemann

, and Wacker

(1973) Basic dyes are inducers of interferon-like activity in mice. Arch Ges Virusforsch 40: 82–85.

13.

DiMarco

Terni

Silvestrini

Scarpinato

Bogoli

, and Antonelli

(1968) Effect of daunomycn on Herpes Virus hominis in human cells. Giorn Microbiol 16: 25–35.

14.

Frederick

C.A.

Williams

L.D.

Ughetto

van der Marel

G.A.

van Boom

J.H.

Rich

, and Wang

A.H.-J.

(1990) Structural comparison of anticancer drug–DNA complexes: adriamycin and daunomycin. Biochemistry 29: 2538–2549.

15.

Gabbay

E.J.

Grier

Fingerle

R.E.

Reimer

Levy

Pearce

S.W.

, and Wilson

W.D.

(1976) Interaction specificity of the anthracyclines with deoxyribonucleic acid. Biochemistry 15: 2062–2070.

16.

Jamison

J.M.

Flowers

D.G.

Jamison

Kitareewan

Krabill

Rosenthal

K.S.

, and Tsai

C.-C.

(1988) Enhancement of the antiviral and interferon-inducing activities of poly r(A-U) by carminic acid. Life Sci 42: 1477–1483.

17.

Jamison

J.M.

Bonilla

P.J.

, and Tsai

C.-C.

(1990) Modulation of the antiviral activity of poly r(A-U) by ethidium bromide and propidium iodide. Antiviral Chem Chemother 1: 53–60.

18.

Komiyama

Oki

, and Inui

(1983) Interaction of new anthracycline antibiotics with DNA-Effects on nucleic acid synthesis and binding to DNA. Biochim Biophys Acta 740: 80–87.

19.

Kriebardis

Meng

, and Aktipis

(1984) On the inhibition of the RNA polymerase-catalysed synthesis of RNA by daunomycin. Interference of the inhibitor with elongation and preelongation steps. Biochem Biophys Res Comm 123: 914–920.

20.

Laguex

Page

, and Delorme

(1984) Daunorubicin-albumin copolymer targeting to leukemic cells in vitro and in vivo. Sem Oncol 11(S3): 59–63.

21.

Lenaz

, and Page

J.A.

(1976) Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3: 111–120.

22.

Minor

P.D.

, and Dimmock

N.J.

(1977) Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology 78: 393–406.

23.

Parkison

T.M.

, and Brown

J.P.

(1981) Metabolic fate of food colorants. Ann Rev Nutr 1: 175–205.

24.

P.L. Biochemicals Catalog (1977) No. 105, p.81. Piscataway, NJ.

25.

Research Reference Reagents Note (1975) No. 13. Research Resources Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

26.

Research Reference Reagents Note (1979) No. 16A. J Biol Stand 7: 383–395.

27.

Riggs

C.E.

(1984) Clinical pharmacology of daunorubicin in patients with acute leukemia. Sem Oncol 11(S3): 2–11.

28.

Ross

W.E.

Glaubiger

D.E.

, and Kohn

K.N.

(1978) Protein-associated breaks in cells treated with adriamycin or ellipticine. Biochem Biophys Acta 519: 23–30.

29.

Samuel

C.E.

(1987) Progress toward the understanding of the molecular mechanisms of interferon action. Oncology and immunology of Down syndrome. Prog Clin Biol Res 246: pp. 209–220. Alan R. Liss Inc. NY.

30.

Sehgal

P.B.

Tamm

, and Vilcek

(1975) Enhancement of human interferon production by neutral red and chloroquine: Analysis of inhibition of protein degradation and macromolecular synthesis. J Exp Med 142: 1283–1300.

31.

Shortridge

K.F.

, and Squires

(1977) Effect of daunoribicin on the growth of adenovirus. J Antimicrob Chemother 3: 133–139.

32.

Tewey

K.M.

Rowe

T.C.

Yang

Halligan

B.D.

, and Liu

L.F.

(1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 446–468.

33.

Traganos

(1986) Dihydroxyanthraquinone and related bis(substituted) aminoanthraquinones: a novel class of antitumor agents, In: International Encyclopedia of Pharmacology and Therapeutics, Cell Cycle Effects of Drugs (ed. Dethlefsen

L.A.

), Section 121, pp. 269–286. Pergammon, Elmsford, NY.

34.

Trouet

, and Jolles

(1984) Targeting of daunorubicin by association with DNA or proteins: A review. Sem Oncol 11(S3): 64–77.

35.

Wang

A.H.-J.

Ughetto

Quigley

G.J.

, and Rich

(1987) Interactions between an anthracycline antibiotic and DNA: Molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2 Å resolution. Biochemistry 26: 1152–1163.

36.

Zunino

Gambetta

Di Marco

, and Zaccara

(1972) Interaction of daunomycin and its derivatives with DNA. Biochem Biophys Acta 277: 489–498.

37.

Zwelling

L.A.

Kerrigan

, and Michaels

(1982) Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: Comparison with adriamycin and 4′-(9-acridnylamino) methane sulfon-m-anisidide. Cancer Res 42: 2687–2691.